Complications of the nephrotic syndrome and their treatment

Clinical Nephrology

Volumn 62, Issue 4, 2004, Pages 245-259

  Crew, R J ^a   Radhakrishnan, J ^a   Appel, G ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Edema; Hyperlipidemia; Nephrotic syndrome

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BUMETANIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENOXAPARIN; ERYTHROPOIETIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FUROSEMIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LOOP DIURETIC AGENT; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; METOLAZONE; PENTOXIFYLLINE; PRAVASTATIN; RAMIPRIL; STEROID; TACROLIMUS; TORASEMIDE; TRANDOLAPRIL; UNINDEXED DRUG; WARFARIN;

ANEMIA; BACTERIAL PERITONITIS; BLEEDING; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG MEGADOSE; EDEMA; ENDOCRINE DISEASE; GLOMERULOPATHY; HORMONE DEFICIENCY; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPOALBUMINEMIA; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; HYPOTHYROIDISM; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY VEIN THROMBOSIS; LIPID ANALYSIS; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; NEPHROTIC SYNDROME; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOGENESIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; SODIUM RESTRICTION; THROMBOEMBOLISM; VITAMIN D DEFICIENCY;

EID: 6344219965     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp62245     Document Type: Review

References (95)

1. Al-Mugeiren MM, Gader AMA, Al-Rasheed SA, Bahakim HM, Al-Momen AK, Al-Salloum A 1996 Coagulopathy of childhood nephrotic syndrome - a reappraisal of the role of natural anticoagulants and fibrinolysis. Hemostasis 26: 304-310
2. Al-Shurbaji A, Humble E, Rudling M, Lindenthal B, Berglund L 1998 Hepatic cholesterol metabolism in experimental nephrotic syndrome. Lipids 33: 165-169
3. Alon U, Chan JCM 1984 Calcium and vitamin D homeostasis in the nephrotic syndrome: current status. Nephron 36: 1-4
4. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwynn AP 1995 Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235-1241
5. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS 1985 The hyperlipidemia of the nephrotic syndrome. Relation to the plasma albumin concentration, oncotic pressure, and viscosity. N Engl J Med 312: 1544-1548
6. Bartosik LP, Lajoie G, Sugar L, Cattran D 2001 Predicting progression in IgA nephropathy. Am J Kidney Dis 38: 728-735
7. Bianchi S, Bigazzi R, Caiazza A, Campesse V 2003 A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of renal disease. Am J Kidney Dis 41: 565-570
8. Braschi S, Masson D, Rostoker G, Florentin E, Athias A, Martin C, Jacotot B, Gambert P, Lallemant C, Lagrost L 1997 Role of lipoprotein-bound NEFAs in enhancing the specific activity of plasma CETP in the nephrotic syndrome. Arterioscler Thromb Vasc Biol 17: 2559-2567
9. Brenner B, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, Zhang Z, Shahinfar S 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
10. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan D, Fogo A 2000 Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219-1227
11. Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier C 2003 Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol 14: 1990-1997
12. Chrysostomou A, Becker G 2001 Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925-926
13. Collett JP, Mishal Z, Lesty C, Mirshahi M, Peynet J, Baumelou A, Soria J, Soria C 1999 Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Throm Haemost 82: 1482-1489
14. Dahlen GH, Guyton JR, Attar M, Farmer J, Kautz JA, Gotto Jr AM 1986 Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74: 758-765
15. Demant T, Mathes C, Gütlich K, Bedynek A, Steinhauer HB, Bosch T, Packard CJ, Warwick GL 1998 A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients. Kidney Int 54: 2064-2080
16. De Sain-Van Der Velden MGM, Reijngoud DJ, Kaysen GA, Gadella MM, Voorbij H, Stellaard F, Koomans HA, Rabelink TJ 1998 Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 9: 1474-1481
17. De Stefano V, Martinelli I, Mannuccio Mannucci P, Paciaroni K, Chiusolo P, Casorelli I, Rossi E, Leoni G 1999 The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and G20210A prothrombin mutation. N Engl J Med 341: 801-806
18. Dogra GK, Watts GF, Herrmann S, Thomas MAB, Irish AB 2002 Statin therapy improves brachial artery endothelial function in nephrotic syndrome. Kidney Int 62: 550-557
19. Ducloux D, Bresson-Vautrin C, Chalopin JM 2001 Use of pentoxifylline in membranous nephropathy. Lancet 357: 1672-1673
20. Falk RJ, Jennette JC, Nachman PH 2000 Primary glomerular disease. In: Brenner BM (ed): The kidney. WB Saunders Company, Philadelphia, pp 1263-1349
21. Feinstein E, Kaptein EM, Nicoloff JT, Massry SG 1982 Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol 2: 70-76
22. Feinstein S, Becker-Cohen R, Algur N, Raveh D, Shalev H, Shvil Y, Frishberg Y 2001 Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Am J Kidney Dis 37: 736-742
23. Férraille E, Vogt B, Rousselot M, Barlet-Bas C, Cheval L, Doucet A, Favre H 1993 Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest 91: 1295-1300
24. Fonseca V, Thomas M, Katrak A, Sweny P, Moorhead JF 1991 Can urinary thyroid hormone loss cause hypothyroidism? Lancet 338: 475-476
25. Fried LF, Orchard TJ, Kasiske BL 2001 Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59: 260-269
26. Fuchshuber A, Kuhnemund O, Keuth B, Lutticken R, Michalk D, Querfeld U 1996 Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 11: 468-473
27. Fuiano G, Esposito C, Sepe V, Colucci G, Bovino M, Rosa M, Balletta M, Bellinghieri G, Conte G, Cianciaruso B, Dal Canton A 1996 Effects of hypercholesterolemia on renal hemodynamics: study in patients with nephrotic syndrome. Nephron 73: 430-435
28. Galindo-Rodriguez G, Bustamante R, Esquivel-Nava G, Salazar-Exaire D, Vela-Ojeda J, Vadillo-Buenfil M, Avina-Zubieta JA 2003 Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis. J Rheumatol 30: 2382-2384
29. Gansevoort RT, Vaziri ND, de Jong PE 1996 Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Am J Kidney Dis 28: 274-277
30. Griffin KA, Abu-Amarah I, Picken M, Bidani AK 2003 Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 41: 201-206
31. Grymonprez A, Proesmans W, Van Dyck M, Jans I, Goos G, Bouillon R 1995 Vitamin D metabolites in childhood nephrotic syndrome. Pediatr Nephrol 9: 278-281
32. Haas M, Spargo BH, Conventry S 1995 Increasing incidence of focal segmental glomerulosclerosis among adult nephropathies: a 20-year renal biopsy study. Am J Kidney Dis 26: 740-750
33. Haas M, Meehan SM, Karrison TG, Spargo BH 1997 Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976 to 1979 - 1995 - 1997. Am J Kidney Dis 30: 621-631
34. Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, Brenner BM 1983 Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 71: 91-103
35. Iocoviello L, Di Castelnuovo A, de Knijff P, D'Orazio A, Amore C, Arboretti R, Kluft C, Benedetta Donati M 1998 Polymorphisms in coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 338: 79-85
36. Irish AB 1997 The factor V Leiden mutation and the risk of thrombosis in patients with the nephrotic syndrome. Nephrol Dial Transplant 12: 1680-1683
37. Jespersen B, Eiskjor H, Mogensen CE, Sorensen SS, Pedersen EB 1995 Reduced natriuretic effect of atrial natriuretic peptide in nephrotic syndrome: a possible role of decreased cyclic guanosine monophosphate. Nephron 71: 44-53
38. Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M 1990 Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome. N Engl J Med 323: 579-584
39. Joven J, Simó JM, Vilella E, Camps J, Espinel E, Villabona C 1995 Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clin Chem 41: 908-913
40. Joven J, Espinel E, Simó JM, Vilella E, Camps J, Oliver A 1996 The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. Atherosclerosis 126: 243-252
41. Kashyap ML, Srivastava LS, Hynd BA 1980 Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 35: 29-40
42. Kauffman RH, Veltkamp JJ, Van Tilburg NH, Va Es LA 1978 Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 65: 607-613
43. Khamiseh G, Vaziri ND, Oveisi F, Ahmadnia MR, Ahmadnia L 1991 Vitamin D absorption, plasma concentration, and urinary excretion of 25-hydroxyvitamin D in nephrotic syndrome. Proc Soc Exp Biol Med 196: 210-213
44. Koomans HA, Boer WH, Dorhout Mees EJ 1987 Renal function during recovery from minimal lesions nephrotic syndrome. Nephron 47: 173-178
45. Korbet SM, Schwartz MM, Lewis EJ 1994 Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 23: 773-783
46. Korbet SM, Genchi RM, Borok RZ, Schwartz MM 1996 The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 27: 647-651
47. Kowal J, Figur A, Hitzig W 1963 Renal vein thrombosis and the nephrotic syndrome with complete remission. J Mount Sinai Hospital 30: 47-58
48. Kyle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, Weltermann A, Speiser W, Lechner K, Eichinger S 2000 High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343: 457-462
49. Lewis E, Hunsicker L, Bain R, Rohde R 1994 The effect of angiotensin enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
50. Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rohde R, Raz I 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
51. Liang KH, Vaziri ND 1999 Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int 56: 621-626
52. Lilova MI, Velkovskii IG, Topalov IB 2000 Thromboembolic complications in children with nephrotic syndrome in Bulgaria (1976-1996). Pediatr Nephrol 15: 74-78
53. Llach F, Papper S 1980 The clinical spectrum of renal vein thrombosis: acute and chronic. Am J Med 69: 819-827
54. Llach F 1985 Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 28: 429-439
55. Markowitz GS, Brignol F, Burns ER, Koenigsburg M, Folkert VW 1995 Renal vein thrombosis treated with thrombolytic therapy: case report and brief review. Am J Kidney Dis 25: 801-806
56. Maschio G, Alberti D, Janin G, Locatelli F, Mann J, Motolese M, Ponticelli C, Ritz E, Zucchelli P 1996 Effect of the angiotensin converting enzyme inhibitor benazapril on the progression of chronic renal insufficiency. N Engl J Med 334: 939-945
57. McCarthy LJ, Titus J, Daugherty GW 1963 Bilateral renal vein thrombosis and the nephrotic syndrome in adults. Ann Intern Med 58: 837-857
58. Minutolo R, Andreucci M, Balletta M, Russo D 2000 Effect of posture on sodium excretion and diuretic efficacy in nephrotic patients. Am J Kidney Dis 36: 719-727
59. Moulin P, Appel GB, Ginsberg HN, Tall AR 1992 Increased concentration of plasma cholesterol ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 33: 1817-1822
60. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H 2002 Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17: 798-802
61. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T 2003 Combined treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized trial. Lancet 361: 117-124
62. Navarro JF, Mora C, Muros M, Maca M, Garca J 2003 Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis 42: 264-270
63. Ogi M, Yokoyama H, Tomosugi N, Hisada Y, Ohta S, Takaeda M, Wada T, Naito T, Ikeda K, Goshima S, Takasawa K, Kobayashi K 1994 Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis 24: 427-436
64. Ooi BS, Ooi YM, Pollack VE 1980 Identification of circulating immune complexes in a subpopulation of patients with membranous glomerulonephropathy. Clin Immunol Immunopathol 16: 447-453
65. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH 1993 The increased risk of coronary heart disease associated with the nephrotic syndrome. Kidney Int 44: 638-642
66. Orth SR, Ritz E 1998 The nephrotic syndrome. N Engl J Med 338: 1202-1210
67. Pei Y, Cattran D, Greenwood C 1992 Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int 42: 960-966
68. Praga M, Guttierez E, Gonzalez E, Morales E, Hernandez E 2003 Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14: 1578-1583
69. Radhakrishnan J, Appel AS, Valeri A, Appel GB 1993 The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis 22: 135-142
70. Rodríguez-Iturbe B, Colic D, Parra G, Gutkowska J 1990 Atrial natriuretic factor in the acute nephritic and nephrotic syndromes. Kidney Int 38: 512-517
71. Rostoker G, Durand-Zaleski I, Petit-Phar M, Ben Maadi A, Jazaerli N, Radier C, Rahmouni A, Mathieu D, Vasile N, Rosso J, Meignan M, Rémy P, Lang P, Weil B 1995 Prevention of thrombotic complications of the nephrotic syndrome by the low-molecular weight heparin enoxaparin. Nephron 69: 20-28
72. Ruggenenti P, Perna A, Mosconi L, Matalone M, Garini G, Salvadori M, Zoccali C, Scolari F, Maggiore Q, Tognoni G, Remuzzi G 1997 Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863
73. Sarasin FP, Schifferli JA 1994 Prophylactic oral anticoagulation in nephrotic patients with idiopathic membranous nephropathy. Kidney Int 45: 578-585
74. Sato T, Liang KH, Vaziri ND 2002 Down-regulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 61: 157-162
75. Schrier RW, Fassett RG 1998 A critique of the overfill hypothesis of sodium and water retention in the nephrotic syndrome. Kidney Int 53: 1111-1117
76. Shearer GC, Stevenson FT, Atkinson DN, Jones Jr H, Staprans I, Kaysen G 2001 Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic syndrome. Kidney Int 59: 179-189
77. Spitalewitz S, Porush JG, Cattran D, Wright N 1993 Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 22: 143-150
78. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A 1993 Lipoprotein(a) in nephrotic syndrome. Kidney Int 44: 1116-1123
79. Stenvinkel P, Berglund L, Ericsson S, Alvestrand A, Angelin B, Eriksson M 1997 Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest 27: 169-177
80. Subbaiah PV, Rodby RA 1994 Abnormal acyltransferase activities and accelerated cholesteryl ester transfer in patients with nephrotic syndrome. Metabolism 43: 1126-1133
81. Thabet MA, Challa A, Chan JC, Pandak WM, Heuman DM, Vlahcevic ZR 1993 Studies of alteration of hepatic cholesterol metabolism in puromycin-induced nephrotic syndrome in rats. Kidney Int 44: 789-794
82. Thomas ME, Harris KPG, Ramaswamy C, Hattersly JM, Wheeler DC, Varghese Z, Williams JD, Walls J, Moorhead JF 1993 Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44: 1124-1129
83. Thurman M, Schrier R 2003 Comparative effects of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med 114: 588-598
84. Tonelli M, Moyé L, Sacks F, Cole T, Curham G 2003 Effect of pravastatin on loss of renal function in patients with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605-1613
85. Toto RD, Grundy SM, Vega GL 2000 Pravastatin treatment of very low density, intermediate density, and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. Am J Nephrol 20: 12-17
86. Vande Walle JG, Donckerwolcke RAMG, van Isselt JW, Derkx FHM, Joles JA, Koomans HA 1995 Volume regulation in children with early relapse of minimal-change nephrosis with or without hypovolemic symptoms. Lancet 346: 148-152
87. Vaziri ND, Alikhani S, Patel B, Nguyen Q, Barton CH, Gonzales EV 1988 Increased levels of protein C activity, protein C concentration, total and free protein S in nephrotic syndrome. Nephron 49: 20-23
88. Vaziri ND 1993 Endocrinological consequences of the nephrotic syndrome. Am J Nephrol 13: 360-364
89. Vaziri ND, Liang KH 1995 Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48: 1979-1985
90. Vaziri ND, Liang KH 1996 Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50: 887-893
91. Vaziri ND, Liang KH, Parks JS 2001 Acquired lecithin-cholesterol acyltransferase deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 49: F823-F828
92. Vuong TD, Stroes ESG, Willekes-Koolschijn N, Rabelink TJ, Koomans HA, Joles JA 1999 Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects. Kidney Int 55: 1005-1010
93. Watts GF, Herrmann S, Dogra GK, Playford DA, Best JD, Thomas MAB, Irish A 2001 Vascular function of the peripheral circulation in patients with nephrosis. Kidney Int 60: 182-189
94. Yalçinkaya F, Tümer N, Gorgani AN, Ekim M, Çakar N 1995 Haemostatic parameters in childhood nephrotic syndrome. Int Urol Nephrol 27: 643-647
95. Yamauchi A, Fukuhara Y, Yamamoto S, Yano F, Takenaka M, Imai E, Noguchi T, Tanaka T, Kamada T, Ueda N 1992 Oncotic pressure regulates gene transcripts of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol Cell Physiol 263: C397-C404